

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07K 1/34 // C07N 7/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/00237</b> <b>(43) International Publication Date:</b> 4 January 1996 (04.01.96)
<b>(21) International Application Number:</b> PCT/SE95/00777 <b>(22) International Filing Date:</b> 22 June 1995 (22.06.95)  <b>(30) Priority Data:</b> 9402254-8 23 June 1994 (23.06.94) SE 9500724-1 24 February 1995 (24.02.95) SE  <b>(71) Applicant (for all designated States except US):</b> PHARMACIA AB [SE/SE]; S-171 97 Stockholm (SE). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> WINGE, Stefan [SE/SE]; Fatburskvarngatan 32, S-118 64 Stockholm (SE). <b>(74) Agents:</b> WAHLSTRÖM, Christer et al.; Pharmacia AB, S-112 87 Stockholm (SE).		<b>(81) Designated States:</b> AU, CA, FI, JP, MX, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> FILTRATION  <b>(57) Abstract</b>  The present invention relates to a method of virus-filtering a solution that contains at least one macromolecule, by virtue of the total salt content of the solution lying in the range of from about 0.2 M up to saturation of the solution with the salt concerned. The inventive method reduces the residence time and the extent to which the solution need to be diluted, and optimizes the yield when virus-filtering primarily proteins, polysaccharides and polypeptides. The reduction in virus content is at least as good as with conventional techniques where the total salt content is low. The present invention facilitates virus filtration with the aid of the so-called "dead-end" technique, which affords several process and economic advantages in comparison with the tangential virus-filtering technique normally used. When virus-filtering the plasma protein factor IX, the yield obtained in the virus-filtering stage is increased from about 70 % to above 95 %, by raising the salt content of the solution in accordance with the present invention.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## FILTRATION

### TECHNICAL FIELD

5

The present invention relates to a method of virus-filtering a solution that contains at least one macromolecule, by virtue of the total salt content of the solution lying in the range of from about 0.2 M up to saturation of the solution with the salt concerned. The inventive method reduces the residence time and the extent to which the solution need to be diluted, and optimizes the yield when virus-filtering primarily proteins, polysaccharides and polypeptides. The reduction in virus content is at least as good as with conventional techniques where the total salt content is low. The present invention facilitates virus filtration with the aid of the so-called "dead-end" technique, which affords several process and economic advantages in comparison with the tangential virus-filtering technique normally used. When virus-filtering the plasma protein factor IX, the yield obtained in the virus-filtering stage is increased from about 70% to above 95%, by raising the salt content of the solution in accordance with the present invention.

15

### BACKGROUND OF THE INVENTION

20

The problem of virus contamination of various protein preparations intended for the medication of human beings has received greater notice in recent years. For instance, occasional reports have been submitted concerning, e.g., blood proteins that have been contaminated with hepatitis virus A, hepatitis virus B, hepatitis virus C and/or Human Immunodeficiency Virus (HIV). In keeping with these reports, the authorities of several countries have sharpened their requirements with regard to cleansing protein preparations of their possible virus contaminants.

25

In present-day, conventional techniques, viruses are inactivated with the aid of chemical additives, primarily solvents and detergents, and/or by exposing the viruses to elevated temperatures. The former method has the drawback of functioning solely on virus with lipid envelopes, for instance hepatitis virus B and HIV. The latter technique mentioned above has the drawback that many proteins are thermally unstable at those temperatures required to effectively reduce the contaminating virus.

30

US-A-4,473,494 (assigned to the U.S. Secretary of the Army) discloses a method for production of stroma-free, non-heme protein-free hemoglobin by use of zinc ions to promote precipitation of a zinc ion-bound insoluble hemoglobin complex, followed by  
5 membrane ultrafiltration of the zinc-hemoglobin complex from the filtrate fluid medium. In the only step where viruses are said to be removed from hemoglobin, the total salt content is below 0.05 M, i.e. the total content of salt is conventional.

EP-A-0307373 (assigned to Ares-Serono) relates to removal of viruses and/or other  
10 contaminants from biological materials in fluid form by using ultrafiltration membranes having a 100,000 Da cut-off. A preferred biological material is human growth hormone. In the examples of EP-A-0307373, the total content of salt in the virus-filtering step lies in the range of from 0.01 up to 0.10 M ( $\text{NH}_4\text{CO}_3$ ), i.e. the total content of salt is conventional.

15 There is thus a need for an effective virus-reducing method which can be applied to different types of macromolecules, primarily proteins, and on different types of viruses.

### DESCRIPTION OF THE INVENTION

20 One object of the present invention is to markedly reduce the residence time when virus-filtering solutions that contain macromolecules.

Another object of the present invention is to markedly reduce the liquid volumes when virus-filtering solutions that contain macromolecules.

25 A further object of the present invention is to reduce the filter area required to effectively virus-filter solutions that contain macromolecules.

Yet another object of the present invention is to achieve a macromolecule yield in excess  
30 of about 90% in the virus-filtering stage.

Still another object of the present invention is to reduce the polymerization obtained on the virus filter surface, so as to enable the rate of flow to be increased and the process time to be decreased.

These and other objects are fulfilled by the present invention, which relates to a method of virus-filtering a solution containing at least one macromolecule wherein the total salt content of the solution lies within the range of from about 0.2 M up to saturation of the solution with the salt concerned.

The inventor of this invention has thus found that virus filtration can be effected much more effectively than previously known, by increasing the salt content of the solution. This discovery is surprising, because hitherto in virus filtration of proteins it has been believed that solely the protein concentration, the rate of flow and the pH have had any influence on the process.

It is believed that the enhanced filtering effect achieved at higher salt concentrations is because the protein contracts and can therewith pass more easily through the filter pores. It is also conceivable, that the interaction is reduced between macromolecules themselves and/or between the macromolecules and the material of the filter membrane. It is also conceivable that proteins having a large number of hydrophobic groups are influenced to a greater extent by an elevated salt concentration.

The closer the molecular weight, or relative molecular mass, of the macromolecule lies to the pore size of the filter membrane, the more effective the present invention. The effectiveness of the present invention is also enhanced when the difference in the size and/or the molecular weight of the contaminants and the product increases, i.e. with increasing concentrations of high molecular contaminants in the product.

The present invention also facilitates specific fractions to be separated from a desired product, for instance enables undesirable proteins to be separated from the protein that constitutes the product.

The use of a high salt content according to the present invention, also enables the use of the so-called "dead-end" filtering technique. This preferred embodiment, has several advantages over conventional tangential filtering processes normally applied, especially with a pore size of about 5-30 nm. For instance, the equipment and operating procedures required are much simpler and therewith less expensive. The use of "dead-end" filtration

also reduces the loss of the macromolecule, reduces the process time, increases the permeability of the macromolecule through the filter, and also enables a generally constant concentration of the macromolecule to be achieved over the filter as well as a constant membrane pressure. Another advantage with the dead-end filtering technique, is the fact that scaling-up of virus filtering processes from laboratory to industrial scale is considerably facilitated.

When practicing the present invention, the total salt content of the solution suitably lies within the range of from 0.3 up to 3.0 M, preferably within the range of from 0.4 up to 2.5 M, and more preferably within the range of from 0.6 up to 2.0 M. It is particularly preferred that the total salt content of the solution lies within the range of from 0.8 up to 1.5 M.

When necessary, the total salt content of the solution can be adjusted by adding any acceptable salt. For instance, it is possible to use soluble inorganic salts, soluble organic salts or combinations of such salts. It is assumed that important process advantages are obtained when using salts which exhibit a high salting-out effect in accordance with the so-called Hofmeister series. Reference is here made to S. Glasstone, Textbook of Physical Chemistry, van Nostrand Co., Toronto, 2<sup>nd</sup> edition, April 1946, pp. 1254-1259. The most important examples of anions which have such high salting-out effect are citrate, tartrate, sulfate, acetate and phosphate. Cations that can be used advantageously when practicing the present invention are monovalent cations, such as sodium, potassium and ammonium, as well as divalent cations, such as calcium. Sodium chloride, potassium chloride, sodium acetate and sodium citrate or combinations thereof are particularly preferred salts in accordance with the invention, in view of the advantages that are afforded by pharmaceutically acceptable additives. It is also conceivable to add one or more salts in sequence, when the filtration process is carried out in two or more steps.

A protein concentration within the range of from about 5 up to about 10 mg/ml solution is often recommended for virus filtration. When applying the present invention, it was surprisingly found that solutions having a higher protein concentration, from about 10 up to about 20 mg/ml, could be processed advantageously through the virus filter.

The solution should have a temperature within the range from 0°C up to the temperature at which the protein concerned is denatured. The temperature of the solution suitably lies within the range of from 10°C up to 50°C, preferably from 20°C up to 35°C.

- 5 When practicing the present invention, the solution should have a pH in the range of from about 3 up to about 9, suitably from 4 up to 8. The pH of the protein solution should not lie too close to the isoelectric point of the protein concerned. For instance, in the case of gammaglobulin, a better result is obtained with a pH of 5.5 than with a pH of 6.8.
- 10 In the present invention, solution refers to a solution that contains at least 50 percent by weight of water, optionally including one or more solvents, such as methanol, ethanol, acetone or acetonitrile.

The present invention can be used to optimize process procedures when virus-filtering  
15 solutions that contain a large number of different types of macromolecules. Examples of such molecules are proteins, polysaccharides and polypeptides or combinations thereof. The origin of the macromolecules is irrelevant to the use of the present invention. The macromolecules may thus derive from the plant kingdom or the animal kingdom or may be produced initially by industrial processes. However, the macromolecules are suitably  
20 of human or animal origin or engineered genetically (recombinants).

Particularly appropriate proteins in regard of the present invention are factor VIII, factor IX, antithrombin III, gammaglobulin, albumin, streptokinase, apolipoproteins and growth hormones.

25

A particularly preferred factor IX product is Nanotiv®, which is supplied by Pharmacia AB, Stockholm, Sweden. The advantage with this product is that its specific activity prior to filtration is sufficiently high to enable the use of a filter of very fine structure. This enables the virus concentration to be lowered to an extremely low level, at the same time  
30 as the filtering process itself is very rapid and produces a high yield.

Preferred types of factor VIII are deletion derivatives of recombinant produced factor VIII products. A particularly preferred factor VIII product is r-VIII SQ supplied by Pharmacia AB, Stockholm, Sweden. One advantage with this product is that the recombinant

produced product molecule lacks the inactive intermediate part of the natural factor VIII molecule. This gives the molecule a mean molecular weight of about 170,000. A molecule of this size is particularly suited for filtration with such filters as those which enable a considerable virus reduction to be achieved.

5

Preferred apolipoproteins include apolipoprotein AI (Apo AI), apolipoprotein AII (Apo AII), apolipoprotein AIV (Apo AIV), apolipoprotein E (Apo E) and variants or mixtures thereof. Variants include preforms, fragments and truncated, extended or mutated forms of Apo AI, Apo II, Apo IV and Apo E. Mutated forms in which at least one arginine group has been replaced with a cysteine group are particularly preferred. One such mutated form is Apo A-Milano (Apo A-IM), also produced with recombinant DNA technique by Pharmacia AB, Stockholm, Sweden.

10

Polysaccharides which are particularly preferred in accordance with the present invention are glycosaminoglycans and bacteria polysaccharides. Examples of glycosaminoglycans are heparins, heparin fragments, heparin derivatives, heparan sulfate and hyaluronic acid. A particularly preferred group of glycosaminoglycans is comprised of low molecular weight heparins having a mean molecular weight of up to about 10,000, preferably from 2,000 up to 8,000.

15

According to the present invention, particularly suitable polypeptides are bioactive polypeptides, such as recombinant human growth hormones produced in mammalian cells.

20

The present invention can thus be used to optimize the process of virus-filtering solutions that contain, e.g., proteins, polysaccharides and polypeptides. However, the invention is described in the following with reference to solutions that contain proteins, more specifically proteins that occur naturally in the human organism.

25

Those viruses that may be present in protein solutions will normally be much larger than the proteins themselves. It is thus presumable that viruses can be removed from proteins in accordance with size, for instance by filtration.

30



Viruses that can be removed efficiently with the present invention, can have a size smaller than about 350 nm. The size of the viruses that can be removed, suitably is smaller than 200 nm, preferably smaller than 150 nm. Normally, the viruses that can be removed are larger than about 20 nm, i.e. the approximate size of the parvo virus.

5

The present invention is primarily intended for removing viruses from macromolecules, where the macromolecules are the product of interest. It is, however, within the scope of the invention, to use the present method for separating viruses from macromolecules, where the viruses are the product of interest. An example, is the purification of parvovirus for use as a testing agent, and poliovirus for use a vaccine, wherein e.g. proteins and polysaccharides can be removed by the present method.

10

Virus filtration is normally carried out in a tangential filtering process or in a so-called "dead-end" filtering process. In tangential virus filtration, the protein solution is pumped around at a constant rate of flow on the retention side, while another pump draws the protein solution through the filter by suction. When a given volume has been obtained on the retention side, a buffer is added on the retention side. This procedure is repeated a number of times, as necessary, with the major part of the remaining protein passing through the filter while retaining the virus on the retention side. Such a process is called diafiltration. The filter is normally discarded after each run, to avoid transferring the virus.

15

20

In the case of so-called "dead-end" virus filtration, the same virus filter as that used in tangential virus filtration can be used, although the peripheral equipment and operating procedures are much simpler and less expensive than in the case of tangential virus filtration. Thus, in principle, "dead-end" filtration involves placing the macromolecule-containing solution in a pressure vessel prior to filtration and pressing the solution through the virus filter with the aid of a pressure source, suitably nitrogen (gas).

25

The degree of fineness of filters generally, is normally given as pore size or the approximate molecular weight (relative molecular mass) at which the molecules are stopped by the filter, the so called cut-off. In the present invention, the virus filters can have a cut-off of about 1,000,000, suitably 500,000. To remove small viruses, the virus filters should have a cut-off of 200,000, preferably 100,000. To reach a maximum virus-

30

reduction, the virus filter should have a cut-off slightly higher than the macromolecule which is virus-filtered.

Virus filters are known in the art and are supplied by Millipore from Massachusetts, USA and Asahi Chemical Industry Co., Ltd. from Japan, among others. Millipore supplies filters having two different types of membrane, depending on the size of the protein concerned. For instance, Millipore supplies, among others, Viresolve™/70 for proteins having a molecular weight, or relative molecular mass, of up to about 70,000, and Viresolve™/180 for proteins having a molecular weight of up to about 180,000. This latter filter can be used for monoclonal antibodies, for instance. Asahi Chemical Industry supplies, among other things, Planova™ 35 and Planova™ 15 filters, this latter filter being used to remove smaller viruses, such as the polio virus.

As mentioned before, the choice of filter will depend on the size of the protein concerned, among other things. Factor IX, antithrombin III, human serum albumin (HSA) and Apo A-IM (the dimer) all have a molecular weight of roughly 60,000-70,000, wherein Viresolve™/70, for instance, is a suitable alternative. Gammaglobulin has a molecular weight of about 180,000, wherein Viresolve™/180, for instance, is a suitable alternative. The latter filter is also suitable for use with the recombinant produced factor VIII product, r-VIII SQ, which has a molecular weight of about 170,000, as mentioned before.

The possibility of choosing a fine structure filter also assumes that the protein solution has a high degree of purity prior to filtration. In turn, the use of a fine structure filter is a prerequisite for the ability to produce protein solutions which have a very low virus content in the end product. Thus, in order to be able to reduce the virus concentration to a very low level, there is required a filter of very fine structure, for instance Viresolve™/70. The virus concentration cannot be lowered to quite such a low level when using Viresolve™/180.

The effectiveness, or efficiency, of the filtering stage is influenced by the purity of the protein solution delivered to the filter. In this regard, a high specific activity prior to filtration results in a higher yield in the filtering stage. For instance, in the case of preferred embodiments applied when filtering solutions that contain factor IX, it has been found that the protein yield in the filtering stage can be increased from about 70% to

above 95%. However, when practicing the present invention, it is possible to achieve protein yields of above 90%, even when working with solutions of low specific activity.

5 With the present invention, it is possible to reduce the content of very small non-enveloped viruses, such as the parvovirus, by at least 3 logs, suitably at least 4 logs, and preferably at least 5 logs. The reduction is very good with the tangential technique, but even better with the "dead-end" technique, when applied according to the present invention.

10 According to the invention, virus filtration is preferably carried out at the end of a protein manufacturing sequence, since a high specific activity prior to filtration will result in a higher protein yield in the filtering stage. The present invention is preferably applied as a last purification stage, optionally followed by a stage for adjusting, for instance, protein concentration, salt content or the pH of the end product. A following diafiltration stage  
15 using a UF-membrane may also be applied to remove salts which although advantageous from a process or economic aspect during virus filtration should not be included in the end product. Protein solutions which are ready for administration will normally contain a physiological solution, for instance 0.15 M sodium chloride at a pH of 7, in combination with one or more stabilizers, such as saccharose or amino acids. The virus filtration  
20 process may also be carried out in two or more steps, with or without intermediate process steps.

The present invention effectively reduces the content of virus with lipid envelopes and viruses without lipid envelopes. Examples of viruses without a lipid envelope are the  
25 hepatitis virus A, polio virus and parvo virus, which are relatively small viruses. Examples of viruses with a lipid envelope are the hepatitis virus B, the hepatitis virus C and the Human Immunodeficiency Virus (HIV).

The invention will now be illustrated in more detail with the aid of exemplifying, non-  
30 limiting examples.

### EXPERIMENTAL SECTION

Experiments were carried out in which the sieving coefficient of proteins, or protein permeability factor, was first determined at different filtrate flowrates. The sieving coefficient, or protein permeability factor, is given as  $P/R$ , where  $P$  is the concentration of protein on the permeate side (the filtrate side) measured by absorption at 280 nm ( $A_{280}$ ) and  $R$  is the concentration of protein on the retention side ( $R$ ) measured by absorption at 280 nm ( $A_{280}$ ). The filtrate flowrate which gave the highest sieving coefficient in the absence of polymerization on the filter was then chosen. A yield optimization was also made with some macromolecules.

Example 1

Experiments were carried out with factor IX as the macromolecule, to illustrate the effect of two salt contents on the protein sieving characteristic, the diafiltration volume and the yield. A commercial solution containing factor IX, Nanotiv®, was supplied by Pharmacia AB, Stockholm, Sweden. The solution containing factor IX was obtained from human blood plasma and prior to filtration had been treated in a sequence involving anion exchange, chemical virus inactivation, affinity chromatography and cation exchange. The solution was ultra-filtered between each stage, except between the chemical virus inactivating stage and the affinity chromatographic stage.

10

Experimental conditions:

Degree of purity of the entering protein solution: high.

Buffer: 0.144 M NaCl+0.0055 M sodium citrate.

Total salt content: about 0.15 M.

15 Protein concentration: 0.5-1.0 A<sub>280</sub> units.

Protein solution pH: 7.

Experimental temperature: room temperature (about 23°C).

Virus separating filters: Viresolve™/70.

Filtering technique: tangential.

20 Filter area: 1/3 ft<sup>2</sup>

Retention flowrate: 41 l/h.

Pump: Watson-Marlow 504.

Transmembrane pressure: 0.2-0.3 bar.

TABLE 1

25 Determining the protein sieving coefficient.

Experiment	Filtrate flowrate, ml/min	P/R, %
1	3.5	35.0
2	6.9	39.6
3	10.7	45.8
30 4	14.1	56.2
5	17.6	55.6
6	20.8	58.3
7	24.3	61.7

An optimal filtrate flowrate of 20.8 ml/min was obtained by determining the protein sieving coefficient.

TABLE 2

5 Yield optimization. Filtrate flowrate: 20.8 ml/min. High degree of protein solution purity. Buffer: 0.144 M NaCl+0.0055 M sodium citrate. Total salt content: about 0.15 M.

Experiment	Filtration time	P/R, %
1	3 min 10 s	55.1
2	6 min 25 s	52.1
10 3	10 min 40 s	44.5
4	13 min 20 s	34.0

Diafiltration with a dilution of about 1 volume unit per volume unit of entering protein solution (1+1) resulted in a yield of about 90%.

15

### Example 2

The same conditions were applied as those applied in Example 1, with the exception that in this case the buffer comprised 1.0 M NaCl+0.01 M sodium citrate, which gave a total salt content of about 1.0 M.

20

TABLE 3

Determining the protein sieving coefficient.

Experiment	Filtrate flowrate, ml/min	P/R, %
25 1	3.5	55.2
2	6.9	55.7
3	10.7	61.4
4	14.1	68.4
30 5	17.6	74.2
6	20.8	77.0
7	24.3	80.5

This determination of the protein sieving coefficient gave an optimal filtrate flowrate of 24.3 ml/min.

TABLE 4

5 Yield optimization. Filtrate flowrate: 24.3 ml/min.

	Experiment	Filtration time	P/R, %
	1	2 min 30 s	72
	2	—	68
10	3	7 min 14 s	65
	4	9 min 38 s	55

Diafiltration with a dilution of about 0.3 volume units per volume unit of entering solution (1+0.3) resulted in a yield of > 95%.

15

### Example 3

The virus removing effect achieved with the experiments disclosed in Examples 1 and 2 was determined by a virus study. The study was carried out on parvovirus, which are  
20 non-lipid-enveloped viruses and which have a size of 20-25 nm. In principle, experiments with such viruses fall into the "worst case" category since they are some of the smallest viruses known.

The parvovirus was added to the solutions containing factor IX, with a salt content of  
25 0.144 M NaCl+0.0055 M sodium citrate (experiment 1) and 1.0 M NaCl+0.01 M sodium citrate (experiment 2) respectively. The solutions were then virus-filtered in accordance with Examples 1 and 2. The solutions were analyzed with respect to the parvovirus both before and after virus filtration.

30	Experiment	Virus reduction
	1	$1 \times 10^{3.7}$
	2	$1 \times 10^{4.0}$

The results show that virus filtration in accordance with Examples 1 and 2 fulfil the requirements placed by the authorities on the virus reduction in one process step. Furthermore, the use of a high salt content in accordance with the invention is at least equally as effective in removing virus as previously known techniques.

5

#### Example 4

The same conditions were applied as those applied in Example 1, with the exception that the entering protein solution was not as pure.

10

Diafiltration with dilution of about 3 volume units per volume unit of entering protein solution (1+3) resulted in a yield of about 65%.

#### Example 5

15

The same conditions were applied as those applied in Example 2, with the exception that the entering protein solution was not as pure.

Diafiltration with dilution of about 3 volume units per volume unit of entering protein solution (1+3) resulted in a yield of 89%. The yield of factor IX:C was 87%.

20

#### Example 6

Experiments were carried out with factor IX as the macromolecule, to show the effect of four salt contents on the protein sieving coefficient, the diafiltration volume and the yield, with other experiment conditions being constant. The Nanotiv® solution used was similar to that used in Example 1. The experimental conditions applied were the same as those applied in Example 1.

25



TABLE 5

Determining the protein sieving coefficient. The buffer comprised 0.144 M NaCl+0.0055 M sodium citrate. Total salt content: about 0.15 M.

5	Experiment	Filtrate flowrate, ml/min	P/R, %
	1	3.5	25
	2	6.9	28
	3	14.1	43
	4	20.8	49
10	5	24.3	50

TABLE 6

Determining the protein sieving coefficient. The buffer comprised 0.5 M NaCl+0.01 M sodium citrate. Total salt content: about 0.5 M.

15	Experiment	Filtrate flowrate, ml/min	P/R, %
	1	3.5	36
	2	6.9	44
	3	14.1	61
20	4	20.8	67
	5	24.3	69

TABLE 7

Determining the protein sieving coefficient. The buffer comprised 1.0 M NaCl+0.01 M sodium citrate. Total salt content: about 1.0 M.

25	Experiment	Filtrate flowrate, ml/min	P/R, %
	1	3.5	49
	2	6.9	60
30	3	14.1	72
	4	20.8	74
	5	24.3	76

TABLE 8

Determining the protein sieving coefficient. The buffer comprised 1.5 M NaCl+0.01 M sodium citrate. Total salt content: about 1.5 M.

5	Experiment	Filtrate flowrate, ml/min	P/R, %
	1	3.5	48
	2	6.9	56
	3	14.1	73
	4	20.8	76
10	5	24.3	74

It is evident from Tables 5 to 8 that the present invention provides a marked improvement in the process conditions when virus-filtering factor IX solutions in comparison with previously known techniques where low salt contents have been used.

15

Example 7

Experiments were carried out with factor IX as the macromolecule to show the effect of three different salts on the protein sieving coefficient, the diafiltration volume and the yield, with other experiment conditions being constant. The Nanotiv® solution used was similar to that used in Example 1. The conditions applied were the same as those applied in Example 1.

20

TABLE 9

25 Determining the protein sieving coefficient. The buffer comprised 0.5 M potassium dihydrophosphate. Total salt content: 0.5 M.

	Experiment	Filtrate flowrate, ml/min	P/R, %
	1	3.5	34
30	2	6.9	48
	3	14.1	57
	4	20.8	55

TABLE 10

Determining the protein sieving coefficient. The buffer comprised 0.5 M NaCl. Total salt content: 0.5 M.

Experiment	Filtrate flowrate, ml/min	P/R, %
1	3.5	27
2	6.9	43
3	14.1	50
4	20.8	46

10

TABLE 11

Determining the protein sieving coefficient. The buffer comprised 0.5 M barium chloride. Total salt content: 0.5 M.

Experiment	Filtrate flowrate, ml/min	P/R, %
1	3.5	24
2	6.9	36
3	14.1	34
4	20.8	—

20

It will be evident from Tables 9 to 11 that the present invention can be carried out advantageously with a number of different salts. It will also be seen that the protein sieving coefficient increases when using salts that have a high salting-out effect in accordance with the Hofmeister series (potassium dihydrophosphate) in comparison with a salt that has a low salting-out effect (barium chloride).

### Example 8

Experiments were carried out with gammaglobulin as the macromolecule to show the effect of salt content on protein sieving coefficient, diafiltration volume and yield. The solution containing gammaglobulin was a commercial product obtained from blood plasma, Gammonativ®, supplied by Pharmacia AB, Stockholm, Sweden. Prior to filtration, the gammaglobulin solution had been purified by an initial Cohn fractionation followed by a chromatographic stage.

The experimental conditions applied were the same as those applied in Example 1, with the exception that the virus-removing filter was a Viresolve™/180 filter, the pH of the solution was 6.8 and the protein concentration was 2.5-5.0 A<sub>280</sub> units. The buffer comprised 2.2% albumin+0.15 M NaCl+0.02 M NaAc+0.075 M glycine. Total salt content: 0.17 M.

TABLE 12

Determining the protein sieving coefficient.

10

Experiment	Filtrate flowrate, ml/min	P/R, %
1	3.5	32
2	6.9	35
3	10.7	41
15 4	14.1	51
5	17.6	59
6	20.8	63
7	24.3	69

20 Determination of the protein sieving coefficient gave an optimal filtrate flowrate of 20.8 ml/min.

#### Example 9

25 The same conditions were applied as those applied in Example 8, with the exception that in this case the buffer comprised 2.2% albumin+1.0 M NaCl+0.02 M NaAc+0.075 M glycine. Total salt content: about 1.0 M.

TABLE 13

Determining the protein sieving coefficient.

	Experiment	Filtrate flowrate, ml/min	P/R, %
5	1	3.5	38
	2	6.9	57
	3	10.7	64
	4	14.1	71
	5	17.6	75
10	6	20.8	80
	7	24.3	81

Determination of the protein sieving coefficient gave an optimal filtrate flowrate of 20.8 ml/min.

15

Optimization of the yield at a filtrate flowrate of 20.8 ml/min. and a residence time of up to 10 min gave a P/R quotient of between 60% and 68%.

Diafiltration with a dilution degree of about 1 volume unit per volume unit of entering protein solution (1+1) resulted in a yield of 90%.

20

#### Example 10

The same conditions were applied as those applied in Example 8, with the exception that in this case the pH of the solution was 5.5.

25

TABLE 14

Determining the protein sieving coefficient.

	Experiment	Filtrate flowrate, ml/min	P/R, %
30	1	3.5	41
	2	6.9	47
	3	14.1	62
	4	20.8	72
	5	24.3	74

Example 11

The same conditions were applied as those applied in Example 10, with the exception that  
5 in this case the buffer comprised 2.2% albumin+1.0 M NaCl+0.02 M NaAc+0.075 M  
glycine. Total salt content: about 1.0 M.

TABLE 15

Determining the protein sieving coefficient.

10

Experiment	Filtrate flowrate, ml/min	P/R, %
1	3.5	57
2	6.9	67
3	14.1	78
15 4	20.8	88
5	28.1	90

Example 12

20 Experiments were carried out with albumin as the macromolecule to show the effect of  
salt content on protein sieving coefficient, diafiltration volume and yield. The 4% solution  
containing Human Serum Albumin (HSA) obtained from blood plasma was supplied by  
Pharmacia AB, Stockholm, Sweden. Prior to filtration, the albumin-containing solution  
had been purified by combined Cohn fractionation and a chromatographic stage.

25

The experimental conditions applied were the same as those applied in Example 1, with  
the exception that the protein concentration was about 10 A<sub>280</sub> units. The buffer comprised  
0.15 M NaCl+0.02 M NaAc, resulting in a total salt content of 0.17 M.

TABLE 16

Determining the protein sieving coefficient.

Experiment	Filtrate flowrate, ml/min	P/R, %
5	1	3.5
	2	6.9
	3	14.1
	4	20.8
	5	24.3
		34
		39
		50
		51
		50

10

Determination of the protein sieving coefficient resulted in an optimal filtrate flowrate of 20.8 ml/min.

### Example 13

15

The same conditions were applied as those applied in Example 12, with the exception that in this case the buffer comprised 1.0 M NaCl+0.02 M NaAc, resulting in a total salt content of about 1.0 M.

20

TABLE 17

Determining the protein sieving coefficient.

Experiment	Filtrate flowrate, ml/min	P/R, %
25	1	3.5
	2	6.9
	3	14.1
	4	20.8
	5	24.3
		39
		57
		62
		64
		60

30 Diafiltration with a dilution degree of about 1 volume unit per volume unit of entering protein solution (1+1) resulted in a yield of 85%.

Example 14

Experiments were carried out with factor IX as the macromolecule, to show the effect of the retention flowrate on the protein sieving coefficient with other conditions constant.

The commercial Nanotiv® solution used was similar to the solution used in Example 1.

- 5 The conditions applied were the same as those applied in Example 1, with the exception that in this case the buffer comprised 1 M NaCl+6.4 mM sodium citrate with a pH of 7.0.

TABLE 18

Determining the protein sieving coefficient at different retention flowrates.

	Experiment	Retention flowrate, l/h	Filtrate flowrate, ml/min	P/R%
	1	1	14	79
	2	1	19	85
	3	1	24	85
	4	10	14	72
15	5	10	19	76
	6	10	24	76
	7	20	14	62
	8	20	19	70
	9	20	24	76
20	10	30	14	65
	11	30	19	69
	12	30	24	73
	13	40	14	60
	14	40	19	64
25	15	40	24	70
	16	50	14	57
	17	50	19	61
	18	50	24	68
	19	60	14	51
30	20	60	19	56
	21	60	24	62
	22	90	14	46
	23	90	19	56
	24	90	24	56



Lower retention flowrates result in higher protein permeability through the filter.

### Example 15

5

Experiments were carried out with factor IX as the macromolecule in a solution having a high salt content, to show the effect of type of virus-filtering technique on dilution, yield, protein sieving coefficient and process time, with other experimental conditions being essentially constant. The experimental conditions applied, including the Nanotiv® solution were the same as those applied in Example 1, with the exception of the following differences:

Virus filtration technique	Tangential	"Dead-end"
15 Amount of protein solution		
prior to virus filtration (g):	294	1124
Protein conc. ( $A_{280}$ units):	0.66	1.0
Retention flowrate (l/h):	40	0
Filtrate flowrate buffer		
20 (ml/min):	24	28

TABLE 19

Determining dilution, yield, protein sieving coefficient and process time using different virus-filtering techniques.

25

Virus filtration technique	Tangential	"Dead-end"
Amount of protein solution		
after virus filtration (g):	459	1146
30 Dilution:	1 + 0.56	1 + 0.02
Yield (%):	89	94
Protein sieving coefficient		
(P/R in %):	17-64	92-98

TABLE 19 (cont.)

Determining dilution, yield, protein sieving coefficient and process time using different virus-filtering techniques.

5	Virus filtration technique	Tangential	"Dead-end"
	Actual filtrate flowrate (ml/min):	15-24	7-25
	Process time (kIU factor IX/h):	31	105
10	Protein load (A <sub>280</sub> units/ft <sup>2</sup> ):	413	2360

Virus filtration of factor IX using the "dead-end" technique means less dilution, shorter process times and results in a higher yield and protein permeability.

15

#### Example 16

Experiments were carried out with factor IX as the macromolecule, to show the effect of salt content on yield and the protein sieving coefficient when virus-filtering in accordance with the "dead-end" technique, with remaining experimental conditions constant. In addition to NaCl, the buffer also contains 6.4 mM sodium citrate (pH 7.0) in both cases. The conditions applied, including the Nanotiv® solution were the same as those applied in Example 1, with the exception of the following differences:

25	Salt content (M NaCl):	1.0	0.15
	Amount of protein solution prior to virus filtration (g):	293	256
	Protein conc. (A <sub>280</sub> units):	0.84	0.84
	Retention flowrate (l/h):	0	0
30	Filtrate flowrate buffer (ml/min):	28	28

TABLE 20

Determining dilution, yield and protein sieving coefficient when using a buffer which contained 1.0 M NaCl+6.4 mM sodium citrate (pH 7.0).

5	Amount of filtrate, g	P/R, %	Flowrate, ml/min
	50	83	31
	100	82	28
	150	84	30
	200	81	23
10	250	81	21

		Protein conc.,		
Sample	Amount, g	A <sub>280</sub> units	Yield, %	
15	Prior to virus			
	filtration	293	0.84	100
	Filtrate	284	0.67	77
	Wash	30	0.47	6

- 20 A total yield of 83% was obtained over the virus filter, with a dilution degree of 1+0.07. Process time 264 kIU factor IX/h.

TABLE 21

- 25 Determining dilution, yield, protein sieving coefficient and process time when using a buffer containing 0.15 M NaCl+6.4 mM sodium citrate (pH 7.0).

	Amount of filtrate, g	P/R, %	Flowrate, ml/min
	50	61	22
	100	62	20
30	150	63	18
	200	63	16

Sample	Amount, g	Protein conc.,	Yield, %
		A <sub>280</sub> units	
Prior to virus			
5 filtration	256	0.84	100
Filtrate	243	0.50	56
Wash	30	0.50	7

A total yield of 63% was obtained with the virus filter, with a dilution degree of 1+0.07.

10 Process time 194 kIU factor IX/h.

#### Example 17

Experiments were carried out with antithrombin (AT III) as the macromolecule in a  
 15 solution of low salt content, to show the effect of this type of virus filtration technique on  
 dilution, yield, protein sieving coefficient and process time, with other conditions being  
 essentially constant. The commercial ATenativ® solution used was delivered by  
 Pharmacia AB, Stockholm, Sweden. The buffer contained 0.12 M NaCl+1 mM sodium  
 phosphate (pH 7.4) in both cases. The conditions applied were the same as those applied  
 20 in Example 1, with the exception of the following differences:

Virus filtration technique		Tangential	"Dead-end"
Amount of protein solution			
25	prior to virus filtration (g):	967	970
	Protein conc. (A <sub>280</sub> units):	9.1	9.1
	Retention flowrate (l/h):	40	0
Filtrate flowrate buffer			
	(ml/min):	24	24

30

TABLE 22

Determining dilution, yield, protein sieving coefficient and process time with the aid of different virus filtration techniques.

	Virus filtration technique	Tangential	"Dead-end"
	Amount of protein solution after virus filtration (g):	1692	989
	Dilution:	1 + 0.75	1 + 0.02
10	Yield (%):	97	97
	Protein sieving coefficient (P/R in %):	73-86	95-98
	Actual filtrate flowrate (ml/min):	15-24	8-14
15	Process time (kIU AT III/h):	37	53
	Protein load (A <sub>280</sub> units/ft <sup>2</sup> ):	18477	18481
	Filtration efficiency (1/m <sup>2</sup> filter*h):	9	12

20

Virus filtration of AT III when applying the "dead-end" technique means less dilution, affords higher protein permeability and shorter process times.

#### Example 18

25

Experiments were carried out with antithrombin (AT III) as the macromolecule, to show the effect of salt content on yield and protein permeability (sieving coefficient) when virus-filtering in accordance with the tangential technique, with remaining experimental conditions being constant. In addition to NaCl, the buffer contained 1 mM sodium phosphate (pH 7.4) in all experiments. The conditions applied, including the ATenativ® solution, were the same as those applied in Example 17, with the exception that the retention flowrate was 20 l/h in all experiments.

30

TABLE 23

Determining the protein sieving coefficient at different salt contents and different filtrate flowrates.

5	Experiment	Salt content,	Filtrate flowrate	P/R
		M NaCl	ml/min	%
	1	0.15	14	79
	2	0.15	19	84
	3	0.15	24	87
10	4	1.0	14	87
	5	1.0	19	90
	6	1.0	24	89

High salt content result in improved protein permeability with regard to AT III.

15

#### Example 19

Experiments were carried out with Human Serum Albumin (HSA) as the macromolecule in a solution having a high salt content, to show the effect of type of virus filtration technique on dilution, yield, protein permeability and process time, with other experimental conditions being essentially constant. The HSA solution used was similar to the solution used in Example 12. The buffer contained 1.0 M NaCl+20 mM sodium acetate (pH = 7.4) in all experiments. The conditions applied were the same as those applied in Example 1, with the exception of the following differences:

25

25	Virus filtration technique	Tangential	"Dead-end"
	Amount of protein solution		
	prior to virus filtration (g):	200	6460
30	Protein conc. ( $A_{280}$ units):	10	9.2
	Retention flowrate (l/h):	40	0
	Filtrate flowrate buffer		
	(ml/min):	24	28

TABLE 24

Determining dilution, yield, protein sieving coefficient and process time when using tangential virus filtration.

5	Amount of filtrate, g	P/R, %
	50	39
	100	57
	200	62
	300	64
10	350	60

		Protein conc.,		
Sample	Amount, g	A <sub>280</sub> units	Yield, %	
15	Prior to virus			
	filtration	200	10.0	100
	Filtrate	144	7.0	51
	Wash 1	100	4.4	22
	Wash 2	100	4.2	12

20

A total yield of 85% was obtained over the virus filter, with a dilution of 1+0.72. Process time 4615 mg HSA/h.

TABLE 25

25 Determining dilution, yield, protein sieving coefficient and process time when virus-filtering with the "dead-end" technique.

	Amount of protein solution	
	after virus filtration (g):	6380
30	Dilution:	1 + 0.0
	Yield (%):	98
	Protein sieving coefficient	
	(P/R in %):	97-100

TABLE 25 (cont.)

Determining dilution, yield, protein sieving coefficient and process time when virus-filtering with the "dead-end" technique.

5	Actual filtrate flowrate	
	(ml/min):	24-34
	Process time (mg HSA/h):	14895
	Protein load	
	(A <sub>280</sub> units/ft <sup>2</sup> ):	124807
10	Filtering efficiency	
	(l/m <sup>2</sup> filter*h):	34

Virus filtration of HSA when applying the "dead-end" technique means less dilution, and results in a higher yield and higher protein permeability and shorter process times.

15

#### Example 20

Experiments were carried out with gammaglobulin as the macromolecule in a solution of high salt content, to show the effect of this type of virus-filtering technique on dilution, yield, protein sieving coefficient and process time with remaining experimental conditions being essentially constant. The gammaglobulin solution used was similar to the solution used in Example 8. The buffer contained 1.0 M NaCl+20 mM sodium acetate + 0.075 M glycine (pH = 5.5) in all experiments. The conditions applied were the same as those applied in Example 1, with the exception of the following differences:

25

Virus filtration technique		Tangential	"Dead-end"
Amount of protein solution			
	prior to virus filtration (g):	301	400
30	Protein conc. (A <sub>280</sub> units):	5.1	4.9
	Retention flowrate (l/h):	40	0
Filtrate flowrate buffer			
	(ml/min):	24	28
	Transmembrane pressure (bar):	0.2	0.1



TABLE 26

Determining dilution, yield, protein sieving coefficient and process time when using "dead-end" filtration:

5	Amount of filtrate, g	P/R, %	Flowrate, ml/min
	50	92	17
	100	92	12
	150	93	9
10	200	92	8
	250	90	7
	300	88	6
	350	87	5

15	Sample	Amount, g	Protein conc., $A_{280}$ units	Yield, %
	Prior to virus filtration	400	4.9	100
20	Filtrate	350	4.6	82
	Wash	100	2.3	12

A total yield of 94% was obtained over the virus filter, with a dilution degree of 1+0.12.  
Process time 2790 mg gammaglobulin/h.

25

TABLE 27

Determining dilution, yield, protein sieving coefficient and process time when using tangential virus filtration.

30	Amount of protein solution after virus filtration (g):	643
	Dilution:	1 + 1.16
	Yield (%):	92

TABLE 27 (cont.)

Determining dilution, yield, protein sieving coefficient and process time when using tangential virus filtration.

5	Protein sieving coefficient	
	(P/R in %):	43-67
	Actual filtrate flowrate	
	(ml/min):	16-20
	Process time (mg gamma-	
10	globulin/h):	1873
	Protein load	
	(A <sub>280</sub> units/ft <sup>2</sup> ):	3192
	Filtering efficiency	
	(l/m <sup>2</sup> filter*h):	23

15

Virus-filtration of gammaglobulin with the "dead-end" technique involves less dilution, and results in a higher yield and protein permeability and shorter process times.

#### Example 21

20

Experiments were carried out with antithrombin as the macromolecule, to illustrate that the present invention is applicable on an industrial scale by using a substantially bigger filter area (10 ft<sup>2</sup>) than in the previous Examples (1/3 ft<sup>2</sup>). A commercial solution containing antithrombin (AT III), ATenativ®, was supplied by Pharmacia AB, Stockholm,

25

Sweden.

#### Experimental conditions:

Buffer: 1 M NaCl+1 mM sodium phosphate.

Total salt content: about 1.0 M.

30 Protein concentration: 9.2 A<sub>280</sub> units.

Protein solution pH: 7.4.

Amount of protein solution prior to virus filtration: 20.8 kg

Virus separating filters: Viresolve™/70.

Filtering technique: dead-end.

Filter area: 10 ft<sup>2</sup>  
 Retention flowrate: 0 l/h.  
 Filtrate flowrate buffer: 20 l/h  
 Transmembrane pressure: 0.3 bar.

5

TABLE 28

Determining dilution, yield, protein sieving coefficient and process time when using a filter area of 10 ft<sup>2</sup> and dead-end filtering technique according to the invention.

10	Amount of protein solution after virus filtration (kg):	24.1
	Dilution:	1 + 0.16
	Yield (%):	96
	Protein sieving coefficient	
15	(P/R in %):	94-97
	Actual filtrate flowrate (ml/min):	7-12
	Process time (kIU AT III/h):	735
	Protein load	
20	(A <sub>280</sub> units/ft <sup>2</sup> ):	19,136
	Filtration efficiency (1/m <sup>2</sup> filter*h):	8.8

It is evident from this Example, that virus filtering antithrombin according to the invention can be applied on an industrial scale with excellent results.

25

### Example 22

The virus-removing effect achieved with the experiments disclosed in Example 15 was determined by a virus study, but at a higher salt content. The virus-filtering technique was the "dead-end" technique. The study was carried out on parvovirus, as in Example 3. The parvovirus was added to the solutions containing factor IX 1.0 M NaCl+0.01 M sodium citrate (experiment 1). The solutions were analyzed with respect to the parvovirus both before and after virus filtration.

30

<u>Experiment</u>	<u>Virus reduction</u>
1	$1 \times 10^{5.5}$

- 5 The results show that virus filtration in accordance with Example 15 using dead-end technique fulfil the requirements placed by the authorities on the virus reduction in one process step. Furthermore, the use of a high salt content in accordance with the invention is at least equally as effective in removing virus as previously known techniques.

CLAIMS

1. A method of virus-filtering a solution containing at least one macromolecule, c h a -  
5 r a c t e r i z e d in that the total salt content of the solution lies within the range of from  
about 0.2 M up to saturation of the solution with the salt concerned.
2. A method according to claim 1, c h a r a c t e r i z e d in that the total salt content of  
the solution lies within the range of from 0.4 up to 2.5 M.
3. A method according to claim 2, c h a r a c t e r i z e d in that the total salt content of  
10 the solution lies within the range of from 0.6 up to 2.0 M.
4. A method according to any previous claim, c h a r a c t e r i z e d in that the salt is  
selected from the group consisting of sodium chloride, potassium chloride, sodium  
acetate and sodium citrate and combinations thereof.
5. A method according to any previous claim, c h a r a c t e r i z e d in that the  
15 macromolecule is selected from the group consisting of proteins, polysaccharides and  
polypeptides and combinations thereof.
6. A method according to claim 5, c h a r a c t e r i z e d in that the macromolecule is  
factor IX.
7. A method according to claim 5, c h a r a c t e r i z e d in that the macromolecule is  
20 gammaglobulin.
8. A method according to claim 5, c h a r a c t e r i z e d in that the macromolecule is  
albumin.
9. A method according to claim 5, c h a r a c t e r i z e d in that the macromolecule is  
antithrombin III.
- 25 10. A method according to claim 5, c h a r a c t e r i z e d in that the macromolecule is a  
deletion derivative of recombinant factor VIII.
11. A method according to any previous claim, c h a r a c t e r i z e d in that the virus-  
filtering process is carried out in accordance with the "dead-end" filtering technique.
12. A method according to any previous claim, c h a r a c t e r i z e d in that the virus-  
30 filtering process reduces the content of non-enveloped viruses by at least 4 logs.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00777

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 1/34 // C07N 7/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, WPIL, CA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0307373 A2 (ARES-SERONO N.V.), 15 March 1989 (15.03.89), the whole document  --	1-12
A	EP 0219295 A2 (NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA), 22 April 1987 (22.04.87), the whole document  --	1-12
A	Dialog Information Services, file 351, DERWENT WPI, Dialog accession no. 9734526, WPI accession no. 94-014376/02, SHIROBOKOV V P, su 1781355 A1 921215 9402 (Basic), the whole document  -- -----	1-12

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

10 October 1995

14-10-1995

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf  
Telephone No. +46 8 782 25 00

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

28/08/95

International application No.

PCT/SE 95/00777

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0307373	15/03/89	SE-T3- 0307373	
		AU-A- 2140888	16/03/89
		CA-A- 1328625	19/04/94
		DE-D, T- 3885686	07/04/94
		ES-T- 2047043	16/02/94
		JP-A- 2000102	05/01/90
EP-A2- 0219295	22/04/87	DE-D, T- 3689562	11/05/94
		ES-T- 2061440	16/12/94
		JP-A- 62281896	07/12/87



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C07K 1/34 // C07N 7/02</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 96/00237</b> (43) International Publication Date: 4 January 1996 (04.01.96)</p>
<p>(21) International Application Number: PCT/SE95/00777 (22) International Filing Date: 22 June 1995 (22.06.95)  (30) Priority Data: 9402254-8 23 June 1994 (23.06.94) SE 9500724-1 24 February 1995 (24.02.95) SE  (71) Applicant (for all designated States except US): PHARMACIA AB [SE/SE]; S-171 97 Stockholm (SE).  (72) Inventor; and (75) Inventor/Applicant (for US only): WINGE, Stefan [SE/SE]; Fatburskvarngatan 32, S-118 64 Stockholm (SE).  (74) Agents: WAHLSTRÖM, Christer et al.; Pharmacia AB, S-112 87 Stockholm (SE).</p>	<p>(81) Designated States: AU, CA, FI, JP, MX, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With a revised version of the international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  (88) Date of publication of the revised version of the international search report: 28 March 1996 (28.03.96)</p>	
<p>(54) Title: FILTRATION</p> <p>(57) Abstract</p> <p>The present invention relates to a method of virus-filtering a solution that contains at least one macromolecule, by virtue of the total salt content of the solution lying in the range of from about 0.2 M up to saturation of the solution with the salt concerned. The inventive method reduces the residence time and the extent to which the solution need to be diluted, and optimizes the yield when virus-filtering primarily proteins, polysaccharides and polypeptides. The reduction in virus content is at least as good as with conventional techniques where the total salt content is low. The present invention facilitates virus filtration with the aid of the so-called "dead-end" technique, which affords several process and economic advantages in comparison with the tangential virus-filtering technique normally used. When virus-filtering the plasma protein factor IX, the yield obtained in the virus-filtering stage is increased from about 70 % to above 95 %, by raising the salt content of the solution in accordance with the present invention.</p>		

\* (Referred to in PCT Gazette No. 14/1996, Section II)



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 1/34 // C12N 7/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, WPIL, CA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0307373 A2 (ARES-SERONO N.V.), 15 March 1989 (15.03.89), the whole document --	1-12
A	EP 0219295 A2 (NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA), 22 April 1987 (22.04.87), the whole document --	1-12
A	Dialog Information Services, file 351, DERWENT WPI, Dialog accession no. 9734526, WPI accession no. 94-014376/02, SHIROBOKOV V P, su 1781355 A1 921215 9402 (Basic), the whole document -- -----	1-12



Further documents are listed in the continuation of Box C.



See patent family annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*B\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

10 October 1995

Date of mailing of the international search report

2 8 FEB 1996

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf  
Telephone No. +46 8 782 25 00

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

05/02/96

International application No.

PCT/SE 95/00777

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0307373	15/03/89	SE-T3- 0307373	
		AU-A- 2140888	16/03/89
		CA-A- 1328625	19/04/94
		DE-D,T- 3885686	07/04/94
		ES-T- 2047043	16/02/94
		JP-A- 2000102	05/01/90
EP-A2- 0219295	22/04/87	DE-D,T- 3689562	11/05/94
		ES-T- 2061440	16/12/94
		JP-A- 62281896	07/12/87



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C07K 1/34 // C07N 7/02	3 A <sup>2</sup>	(11) International Publication Number: WO 96/00237 (43) International Publication Date: 4 January 1996 (04.01.96)
(21) International Application Number: PCT/SE95/00777 (22) International Filing Date: 22 June 1995 (22.06.95)  (30) Priority Data: 9402254-8                      23 June 1994 (23.06.94)                      SE 9500724-1                      24 February 1995 (24.02.95)                      SE  (71) Applicant (for all designated States except US): PHARMACIA AB [SE/SE]; S-171 97 Stockholm (SE).  (72) Inventor; and (75) Inventor/Applicant (for US only): WINGE, Stefan [SE/SE]; Fatburskvarngatan 32, S-118 64 Stockholm (SE).  (74) Agents: WAHLSTRÖM, Christer et al.; Pharmacia AB, S-112 87 Stockholm (SE).	(81) Designated States: AU, CA, FI, JP, MX, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With a revised version of the international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  (88) Date of publication of the revised version of the international search report: 28 March 1996 (28.03.96)	

(54) Title: FILTRATION

## (57) Abstract

The present invention relates to a method of virus-filtering a solution that contains at least one macromolecule, by virtue of the total salt content of the solution lying in the range of from about 0.2 M up to saturation of the solution with the salt concerned. The inventive method reduces the residence time and the extent to which the solution need to be diluted, and optimizes the yield when virus-filtering primarily proteins, polysaccharides and polypeptides. The reduction in virus content is at least as good as with conventional techniques where the total salt content is low. The present invention facilitates virus filtration with the aid of the so-called "dead-end" technique, which affords several process and economic advantages in comparison with the tangential virus-filtering technique normally used. When virus-filtering the plasma protein factor IX, the yield obtained in the virus-filtering stage is increased from about 70 % to above 95 %, by raising the salt content of the solution in accordance with the present invention.

\* (Referred to in PCT Gazette No. 14/1996, Section II)

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 1/34 // C12N 7/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, WPIL, CA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0307373 A2 (ARES-SERONO N.V.), 15 March 1989 (15.03.89), the whole document --	1-12
A	EP 0219295 A2 (NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA), 22 April 1987 (22.04.87), the whole document --	1-12
A	Dialog Information Services, file 351, DERWENT WPI, Dialog accession no. 9734526, WPI accession no. 94-014376/02, SHIROBOKOV V P, su 1781355 A1 921215 9402 (Basic), the whole document -- -----	1-12

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

10 October 1995

Date of mailing of the international search report

2 8 FEB 1996

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

05/02/96

PCT/SE 95/00777

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0307373	15/03/89	SE-T3- 0307373	
		AU-A- 2140888	16/03/89
		CA-A- 1328625	19/04/94
		DE-D, T- 3885686	07/04/94
		ES-T- 2047043	16/02/94
		JP-A- 2000102	05/01/90
<hr/>			
EP-A2- 0219295	22/04/87	DE-D, T- 3689562	11/05/94
		ES-T- 2061440	16/12/94
		JP-A- 62281896	07/12/87
<hr/>			

Form PCT/ISA/210 (patent family annex) (July 1992)